Inhibiting PTPN22 may decrease the risk of autoimmune diabetes

· TGI - Biomarkers, TGI - Health
Authors

A collaborative work of scientists from the University of Würzburg and Joslin Diabetes Center has demonstrated how a genetic variant associated with type 1 diabetes and other autoimmune diseases influences susceptibility to autoimmunity.

English: Overview of the most significant poss...

English: Overview of the most significant possible symptoms of diabetes. See Wikipedia:Diabetes#Signs_and_symptoms for references. Model: Mikael Häggström. To discuss image, please see Template talk:Häggström diagrams (Photo credit: Wikipedia)

Recent studies of the human genome have identified genetic regions associated with autoimmune diseases such as type 1 diabetes. One of these genes is PTPN22, which plays a role in lymphocyte (immune cell) function. A PTPN22 variant (or mutation) has been implicated as a risk factor for type 1 diabetes and several other autoimmune disorders.

When PTPN22 was turned off in mice, mimicking a loss-of-function mutation, the researchers observed an increase in regulatory T cells and a decreased risk of autoimmune diabetes. “This is the first study conducted on the diabetic mouse model that supports the LYP gain-of-function hypothesis,” says Dr. Kissler. “Our work should help to resolve the controversy.”

The Joslin scientists are following up on this study to deepen understanding of how inhibiting PTPN22 affects T and B cells.

The findings appear in the upcoming issue of Diabetes.

Source

Biospace

Sciencedaily

2 Comments

Comments RSS

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: